Search API

0 min read

A recent study published in the Journal of Medical Entomology has shown that the Babesia parasite has rapidly spread throughout the mid-Atlantic region.

Researchers wrote that, to our knowledge, this is the first report of B. microti and B. burgdorferi-positive I. keiransi from Virginia and the first report of B. burgdorferi-positive I. keiransi from Delaware.

This poses a significant health risk to people in communities where the disease was previously considered rare. Humans enter the cycle when bitten by infected ticks.

According to the U.S. CDC, Babesiosis, caused by microscopic parasites that infect red blood cells, can range from asymptomatic to severe illness, particularly in immunocompromised individuals.

The research published on April 22, 2025, highlights an increasing number of locally acquired human cases and the detection of Babesia microti, the primary causative agent of human babesiosis, in blacklegged and Ixodes keiransi ticks.

Little is known about the prevalence of Babesia worldwide, says the CDC, but little is known about its prevalence in malaria-endemic countries, where misidentification as Plasmodium probably occurs. In Europe, most reported cases are due to B. divergens and occur in splenectomized patients.

In the United States, B. microti is the agent most frequently identified (Northeast and Midwest) and can occur in nonsplenectomized individuals.

This study highlighted an unfortunate issue for healthcare providers.

Jurisdictions in the southern mid-Atlantic region should expect babesiosis cases, Lyme disease, and anaplasmosis coinfections during the summer of 2025, and healthcare providers should consider these tick-borne infections as part of the differential diagnosis.

As of May 11, 2025, no approved vaccines are available for these diseases. However, a Lyme disease vaccine has progressed in a phase 3 clinical study.

Vaccine Treats: 
Image: 
Image Caption: 
Dept of Commerce 2025
Live Blog Update Author: 
Location Tags: 
Include in VBT newsletter: 
0 min read

With several countries in the Northern Hemisphere setting new records for measles cases, the United States is unfortunately keeping pace.

In a weekly update, the U.S. Centers for Disease Control and Prevention (CDC) reported an additional 66 measles cases, bringing the national total to 1,001 this year.

As of May 8, 2025, 31 jurisdictions, led by the state of Texas, reported 1,001 confirmed measles cases.

The United States is on track to exceed the 1,279 cases reported in 2019, when an unvaccinated religious group led to cases in several cities, including New York.

To notify international travelers of this health risk, the CDC reissued a Travel Health Advisory in March 2025, identifying 57 countries reporting measles cases.

As of May 11, 2025, the CDC has not included Texas, Ontario, Canada, or Mexico (700+) in its measles advisory.

The CDC writes, 'All international travelers should be fully vaccinated against measles with the measles-mumps-rubella vaccine, including an early dose for infants.'

Vaccine Treats: 
Image: 
Image Caption: 
US CDC May 2025
Live Blog Update Author: 
Location Tags: 
Include in VBT newsletter: 
mpox vaccine
Monkeypox virus risk to children in the United States is low
0 min read

While most Mpox cases have been detected in Africa this year, the UK Health Security Agency (UKHSA) recently reported several instances of both monkeypox virus clades.

On May 8, 2025, the UKHSA confirmed mpox clade Ib and clade IIb cases in England, Northern Ireland, Scotland, and Wales.

Up to the end of April 2025, 12 cases of mpox clade Ib have been reported in England this year. Most of these cases have reported direct or indirect links to travel to countries where mpox clade Ib is circulating, such as the Democratic Republic of Congo and Sierra Leone.

From 2023 to April 2025, 508 cases of mpox clade IIb have been reported in the UK.

Of these, 470 were in England (212 cases were presumed to have acquired mpox in the UK, 155 were acquired outside the UK and 103 are awaiting classification), 19 were in Scotland (4 were supposed to have acquired mpox in the UK, 9 were imported cases acquired outside the UK and six are awaiting classification), 10 were in Wales (4 were presumed to have acquired mpox in the UK, 2 were imported cases acquired outside the UK and four are awaiting classification), and nine were in Northern Ireland (5 were presumed to have acquired mpox in the UK, 3 were imported cases acquired outside the UK and one is awaiting classification).

The UKHSA wrote, 'despite continuing and regular imports of mpox clade IIb, case numbers during 2023 to 2025 likely remain substantially lower than those seen in 2022 due to high levels of vaccine protection suppressing transmission.'

Since June 2022, the UK government has endorsed a vaccination strategy intending to interrupt transmission of the mpox virus in the subset of individuals at increased risk of exposure.

As of May 11, 2025, Bavarian Nordic JYNNEOS® (MVA-BN®, IMVAMUNE®) is available in the United Kingdom and the United States.

Vaccine Treats: 
Image: 
Image Caption: 
UKHSA May 8, 2025
Live Blog Update Author: 
Location Tags: 
Include in VBT newsletter: 
0 min read

With international travel steadily increasing post-pandemic, so have the sales of travel vaccines. 

For example, Denmark's Bavarian Nordic A/S announced today its interim financial results and business progress for the first three months of 2025, which includes travel health revenue increasing by 52% to DKK 680 million compared to the first quarter of 2024.

As of May 9, 2025, the increase is primarily driven by increased demand for rabies and tick-borne encephalitis vaccines.

Furthermore, Bavarian Nordic confirmed positive insights for its mpox and chikungunya vaccines.

Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic, said in a press release, "We had a very strong first quarter for our Travel Health business, demonstrating 52% growth year over year."

"We also recorded our first U.S. sales of the chikungunya vaccine after its approval in February 2025. Our phased launch plan for the vaccine is progressing as planned, with the first European markets coming online over the next couple of months. We are also continuing our efforts to expand the regulatory approvals to other territories."

"Chikungunya represents an increasing public health threat across the globe, and we are proud to have entered our first partnership to improve access to the vaccine for low- and middle-income countries."

Regarding public preparedness, the freeze-dried version of the JYNNEOS® (MVA-BN®, IMVAMUNE®) vaccine was approved by the U.S. Food and Drug Administration (FDA) in March to prevent smallpox and mpox disease in adults.

As of May 2025, clades 1 and 2 of mpox remain global health risks, especially in Africa.

The approval supports the ongoing contract with the U.S. government to stockpile the vaccine. In May, the U.S. government exercised additional options valued at $143.6 million under the existing agreement to supply a freeze-dried formulation of JYNNEOS smallpox vaccine, with planned delivery in 2026.

Overall, the Company's revenue for the first three months increased 62% to DKK 1,347 million.

Vaccine Treats: 
Image: 
Image Caption: 
Fom Pixabay 2025
Live Blog Update Author: 
Location Tags: 
Include in VBT newsletter: 
0 min read

Since the first anthrax fatality in decades was reported in the Kingdom of Thailand in early May 2025, substantial confusion regarding a potential outbreak has been reported on social media.

To clarify the situation as of May 8, 2025, Dr. Pricha Worahan, Public Health Doctor of Nakhon Phanom Province, revealed that the anthrax situation in Mukdahan Province has been continuously monitored.

As for the latest disease situation, there are no confirmed anthrax patients. Anthrax is a zoonotic disease caused by the bacterium Bacillus anthracis.

There was one suspected anthrax patient found, a 55-year-old female farmer who denied any underlying diseases. She had a blister on her right arm that broke in the middle, making the wound black like a cigarette burn.

The doctor initially diagnosed anthrax as suspected, so he collected samples of the blister from her skin and Hemoculture to send to the laboratory of Nakhon Phanom Hospital and Bamrasnaradura Institute. No one with symptoms that fit the definition of searching for contacts of the disease was found.

However, two people who had contact with the infected person did not show any symptoms, and animals in the area did not show any abnormalities or die of unknown causes.

There are no reports of human-to-human transmission of the disease.

The most common vectors are cows, buffalo, goats, and sheep. Infected animals will have fever, be lethargic, not eat, get sick for no apparent reason, and die. Most people get infected by direct contact with infected animals, such as butchering meat, consuming raw or undercooked meat, or coming into contact with animal skins or fur that contain spores of the disease.

The germs contaminate the area where an animal is sick or dies and can remain there for months or years. Patients will have fever, body aches, cough, difficulty breathing, a blue face, and die from respiratory failure.

According to the U.S. CDC, anthrax is rare in the United States, but outbreaks do happen in wild and domestic grazing animals such as cattle or deer. In the U.S., veterinarians recommend yearly livestock vaccination in areas where animals have had anthrax. Additionally, anthrax vaccines for people are available in 2025.

Recently, South Korea approved BARYTHRAX, the world's first recombinant anthrax vaccine, jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency.

BARYTHRAX utilizes protective antigen (PA) proteins produced through genetic recombination techniques. With an anthrax infection, PA is a gateway for 2 Bacillus anthracis toxins, lethal factor and edema factor, to enter host cells. BARYTHRAX vaccination can train and stimulate an immune response to neutralize anthrax by utilizing PA proteins.

Vaccine Treats: 
Image: 
Image Caption: 
Google Maps May 9, 2025
Live Blog Update Author: 
Location Tags: 
Include in VBT newsletter: 
0 min read

With about 8 million cases annually, gonorrhea is one of the most common sexually transmitted infections, without a U.S. FDA-approved vaccine available.

However, another study has concluded that leveraging an existing vaccine provides some cross-protection against N. gonorrhoeae.

Published by the journal Vaccine (Volume 56, 22 May 2025, 127180), this study evaluates the potential effectiveness of outer membrane vesicle (OMV)-based meningococcal B vaccines in preventing this sexually transmitted infection.

A recent review and meta-analysis, which included nine studies, found a pooled vaccine effectiveness of 30% when a 4CMenB vaccine was administered.

The University of West Attica researchers concluded, "While randomized clinical trials are necessary, the findings of this systematic review and meta-analysis highlight the potential effectiveness of OMV-based vaccines in preventing gonorrhea."

This new research, along with previous studies, suggests that the four-component serogroup B meningococcal vaccine (4CMenB) and other OMV-based MenB vaccines might offer such protection against this disease.

4CMenB vaccinations are offered at many community pharmacies in the United States in 2025.

Vaccine Treats: 
Image: 
Image Caption: 
by Marcela P.
Live Blog Update Author: 
Location Tags: 
Include in VBT newsletter: 
0 min read

With millions of people planning to visit the Republic of the Philippines during the summer of 2025, the United States government has recently updated various travel advisories.

On May 8, 2025, the Department of State reissued its Level 2: Exercise Increased Caution due to civil unrest in some areas of the Philippines. This advisory says do not travel to:

The Sulu Archipelago, including the southern Sulu Sea and Marawi City in Mindanao,

And reconsider visiting other areas of Mindanao this year.

Due to these risks, the State Department wrote that U.S. government employees working in the Philippines must obtain special authorization to travel to these areas.

If you visit the Philippines in 2025, enroll in the Smart Traveler Enrollment Program to receive digital alerts and help locate you in an emergency.

Last month, the U.S. Embassy Manila announced 'Beat the Summer Rush – Renew Your Passport Today.'

Appointments for routine consular services are currently available with little to no wait at the U.S. Embassy and the Consular Agency in Cebu.  As summer approaches, demand will rise, making it harder to schedule convenient times. Apply now to avoid the busy season!

From a health risk perspective, the Centers for Disease Control and Prevention (CDC) has included the Philippines in two Travel Health Advisories in 2025.

The CDC's dengue advisory was issued in April, and a global measles advisory was issued in March.

While dengue vaccines are unavailable in the U.S., MMR vaccines are readily offered at travel clinics and pharmacies.

Furthermore, the CDC says international travelers should check the list of routine vaccines and medicines and visit a healthcare provider at least a month before departing abroad this summer.

Vaccine Treats: 
Image: 
Image Caption: 
Google Maps May 8, 2025
Live Blog Update Author: 
Location Tags: 
Include in VBT newsletter: 
0 min read

According to the World Health Organization (WHO), more than 13 million dengue cases were reported in 2024, the highest number on record.

According to recent data, the dengue global outbreak has continued in 2025.

To reduce the health impact of this mosquito-transmitted viral infection, more people than ever were immunized with a dengue vaccine.

Announced today by Japan-based Takeda, the only WHO-listed dengue vaccine QDENGA®'s Q4 FY2024 (April 2024-March 2025), Revenue was JPY 35.6 billion ($247,746,985), an increase of 259%.

QDENGA® (TAK-003) is a tetravalent, two-dose vaccine approved for preventing dengue fever and/or Severe Dengue caused by any of the four serotypes of the dengue virus. 

As of May 8, 2025, QDENGA was authorized in about 40 countries, with authorizations pending in the Philippines and India. 

Unfortunately, no dengue vaccine is available in the United States, even in Puerto Rico, were dengue has become endemic.

Vaccine Treats: 
Image: 
Image Caption: 
Takeda May 8, 2025
Live Blog Update Author: 
Location Tags: 
Include in VBT newsletter: 
vaccine
Chikungunya vaccines available in May 2025